Dexamethasone decreases plasma levels of the prochiral fenbendazole and its chiral and achiral metabolites in sheep

References

• ALVAREZ, L, SANCHEZ, S. and LANUSSE, C., 1997, Modified plasma and abomasal disposition of albendazole in nematode-infected sheep. Veterinary Parasitology, 69, 241–253.
   PubMedGoogle Scholar
• BENCHAOUI, H. and MCKELLAR, Q., 1996, Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. Journal of Pharmacy and Pharmacology, 48, 753–759.
   PubMed Web of Science ®Google Scholar
• BENOIT, E., BESSE, S. and DELATOUR, P., 1992, Effect of repeated doses of albendazole on enantiomerism of its sulphoxide metabolite in goats. American Journal of Veterinary Research, 53, 1663–1665.
   PubMed Web of Science ®Google Scholar
• BERETTA, C., FADINI, L., MALVISI STRACCIARI, J. and MONTESISSA, C., 1987, In vitro Febantel transformation by sheep and cattle ruminal fluids and metabolism by hepatic subcellular fractions from different animal species. Biochemical Pharmacology, 36, 3107–3114.
   PubMed Web of Science ®Google Scholar
• CAMPBELL, W. and HALUSHKA, P., 1996, Lipid derived autacoids, eicosanoids and platelets-activity factors. In J. G. Hardman, A. G. Gilman and L. E. Limbird (eds), Goodman CI Gilman's The Pharmacological Basis of Therapeutics, 9th edn (New York: McGraw-Hill), pp. 601–616.
   Google Scholar
• CRISTOFOL, C., VIRKEL, G., ALVAREZ, L., SANCHEZ, S ARBOIX, M. and LANUSSE, C., 2001, Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. Journal of Veterinary Pharmacology and Therapeutics, 24, 117–124.
   Google Scholar
• DELATOUR, P., BENOIT, E., GARNIER, F. and BESSE, S., 1990, Chirality of the sulphoxide metabolites of fenbendazole and albendazole in sheep. Journal of Veterinary Pharmacology and Therapeutics, 13, 361–366.
   PubMed Web of Science ®Google Scholar
• GALTIER, P., ALVINERIE, M. and DELATOUR, P., 1986, In vitro sulfoxidation of albendazole by ovine liver microsomes: assay and frequency of various xenobiotics. American Journal Veterinary Research, 47, 447–450.
   PubMed Web of Science ®Google Scholar
• GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics, 2nd edn (New York: Marcel Dekker), pp. 45–109.
   Google Scholar
• GOKBULUT, C., NOLAN, A. and MCKELLAR, Q., 2002, Plasma disposition, faecal excretion and in vitro metabolism of oxibendazole following oral administration in horses. Research in Veterinary Science, 72, 11–15.
   PubMedGoogle Scholar
• HENNESSY, D., ALI, D. and S IL INCE, J., 1995, The effect a short-term reduction in feed on the phamacokinetics and efficacy of albendazole in sheep. Australian Veterinary Journal, 72, 29–30. JUNG, H., HURTADO, M., MEDINA, T., SANCHEZ, M. and SOTELO, J., 1990, Dexamethasone increases plasma levels of albendazole. Journal of Neurology, 237, 279–280.
   Google Scholar
• LANUSSE, C., NARE, B. and PRICHARD, R., 1993, Comparative sulphoxidation of albendazole by sheep and cattle liver microsomes and the inhibitory effect of methimazole. Xenobiotica, 23, 285-295. LANUSSE, C. and PRICHARD, R., 1993, Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug Metabolism Review, 25, 235–279.
   PubMed Web of Science ®Google Scholar
• LIN, J., CHIBA, M. and BA ILL 1E, T., 1999, Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacological Reviews, 51, 135–157.
   Google Scholar
• MCKELLAR, Q., GALBRAITH, E. and BAXTER, P., 1993, Oral absorption and bioavailability of fenbendazole in the dog and the effects of concurrent ingestion of food. Journal of Veterinary Pharmacology and Therapeutics, 13, 223–227.
   Google Scholar
• MCKELLAR, Q. A., GOKBULUT, C., MUZANDU, K. and BENCHAOUI, H., 2002, Fenbendazole pharmacokinetics, metabolism and potentiation in horses. Drug Metabolism and Disposition, 30, 1230–1239.
   PubMed Web of Science ®Google Scholar
• MONOSTORY, K. and VERECZKEY, L., 1994, The effect of phenobarbital and dexamethasone co-administration on the activity of rat liver P-450 system. Biochemical and Biophysical Research Communications, 203, 351–358.
   PubMedGoogle Scholar
• MURRAY, M., HUDSON, A. and YASSA, V., 1992, Hepatic microsomal metabolism of the anthelmintic benzimidazole fenbendazole: enhanced inhibition of cytochrome P450 reactions by oxidized metabolites of the drug. Chemical Research Toxicology, 5, 60–66.
   PubMed Web of Science ®Google Scholar
• SANCHEZ, S., ALVAREZ, L. and LANUSSE, C., 1996, Nutritional condition affects the disposition kinetics of albendazole in cattle. Xenobiotica, 26, 307–320.
   PubMed Web of Science ®Google Scholar
• SANCHEZ, S., ALVAREZ, L. and LANUSSE, C., 1997, Fasting induced changes on the pharmacokinetic behaviour of albendazole and its metabolites in cattle. Journal of Veterinary Pharmacology and Therapeutics, 20, 38–47.
   PubMed Web of Science ®Google Scholar
• SANCHEZ, S., ALVAREZ, L., Pis, A., QUIROGA, M. and LANUSSE, C., 1999, Differences on the plasma and abomasal fluid kinetics of albendazole and its metabolites in calves grazed in pasture or fed a grain based diet. Research in Veterinary Science, 66, 223–230.
   PubMedGoogle Scholar
• SANCHEZ, S., ALVAREZ, L., SALLOVITZ, J. and LANUSSE, C., 2000, Enhanced plasma and target tissues availabilities of albendazole and its metabolites in fasted calves: evaluation of different fasting intervals. Journal of Veterinary Pharmacology and Therapeutics, 23, 193–201.
   PubMedGoogle Scholar
• SANCHEZ, S., JONES, D. G., SMALL, J. and MCKELLAR, Q. A., 2002, Intravenous racemic and chiral pharmacokinetic behaviour of oxfendazole co-administered with piperonyl butoxide in sheep. Journal of Veterinary Pharmacology and Therapeutics, 25, 7–14.
   PubMedGoogle Scholar
• SOTELO, J. and JUNG, H., 1998, Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clinical Pharmacokinetics, 34, 503–515.
   PubMed Web of Science ®Google Scholar
• SOUHAILI-EL AMRI, H., MOTHE, 0., TOTIS, M., MASSON, C., BATT, A., DELATOUR, P. and SIEST, G., 1988, Albendazole sulfonation by rat liver cytochrome P-450c. Journal of Pharmacology and Experimental Therapeutics, 246, 758–764.
   Google Scholar
• TAKAYANAGUI, 0., LANCHOTE, V., MARQUES, M. and BONATOR, P., 1997, Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulphoxide with dexamethasone. Therapeutic Drug Monitoring, 19, 51–55.
   Google Scholar
• VIRKEL, G., 2001, Biotransformación hepatica y extra-hepatica de farmacos benzimidazoles en rumiantes. PhD thesis, Universidad Nacional del Centro de la Provincia de Buenos Aires, Argentina.
   Google Scholar
• VIRKEL, G., LIFSCHITZ, A., Pis, A. and LANUSSE, C., 2002, In vitro ruminal biotransformation of benzimidazole sulphoxide anthelmintics: enantioselective sulphoreduction in sheep and cattle. Journal of Veterinary Pharmacology and Therapeutics, 25, 15–23.
   PubMedGoogle Scholar
• YOSHINO, K., KATOH, N., TAKAHASHI, K. and YUAS A., 1993, Possible involvement of protein kinase C with induction of haptoglobin in cows by treatment with dexamethasone and by starvation. American Journal of Veterinary Research, 54, 689–694.
   PubMedGoogle Scholar
• ZIEGLER, D., 1989, S-oxygenases in chemistry and biochemistry. In L. A. Damani (ed.), Sulphur-containing Drugs and Related Organic Compounds, vol. 2, part A (Chichester: Ellis Horwood), pp. 53–66.
   Google Scholar